Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment

Teiji Kuzuya(Nagoya University), Mitsuhiro Fujishiro(Bunkyo University), Yoji Ishizu(Nagoya University), Masatoshi Ishigami(Nagoya University), Tetsuya Ishikawa(Nagoya University), Takashi Honda(Osaka Hospital), Takanori Ito(Aichi Medical University Hospital), Yoshiki Hirooka(Fujita Health University Hospital)
Hepatology Research
April 30, 2019
10.1111/hepr.13358
Cited by 51

Related Papers

Application of artificial intelligence using a convolutional neural network for detecting gastric cancer in endoscopic images
|Gastric Cancer|2018|742
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
|Gut|2019|732
Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer
|Digestive Endoscopy|2015|575
Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition)
|Digestive Endoscopy|2020|510
Diagnostic outcomes of esophageal cancer by artificial intelligence using convolutional neural networks
|Gastrointestinal Endoscopy|2018|470